Literature DB >> 27585400

2-O, 3-O Desulfated Heparin Blocks High Mobility Group Box 1 Release by Inhibition of p300 Acetyltransferase Activity.

Shuo Zheng1, Apparao B Kummarapurugu1, Daniel K Afosah2, Nehru Viji Sankaranarayanan2, Rio S Boothello2, Umesh R Desai2, Thomas Kennedy3, Judith A Voynow1.   

Abstract

High mobility group box 1 (HMGB1) is an alarmin released from macrophages after infection or inflammation and is a biomarker of lung disease progression in patients with cystic fibrosis. We reported that 2-O, 3-O desulfated heparin (ODSH) inhibits the release of HMGB1 from murine macrophages triggered by neutrophil elastase both in vivo and in vitro. HMGB1 shuttles between the nucleus and the cytoplasm. When acetylated at lysine residues in the nuclear localization signal domains, HMGB1 is sequestered in the cytoplasm and is fated for secretion. In this study, we investigated the mechanism by which ODSH blocks HMGB1 secretion. We tested whether ODSH inhibits the activity of p300, a histone acetyltransferase that has been linked to HMGB1 acetylation and release. ODSH inhibited both neutrophil elastase and LPS-triggered HMGB1 release from the murine macrophage cell line RAW264.7 in a concentration-dependent manner. Fluorescein-labeled ODSH was taken up by RAW264.7 cells into the cytoplasm as well as the nucleus, suggesting an intracellular site of action of ODSH for blocking HMGB1 release. ODSH inhibited RAW264.7 cell nuclear extract, human macrophage nuclear extract, and recombinant p300 HAT activity in vitro, resulting in the failure to acetylate HMGB1. In silico molecular modeling predicted that of the numerous possible ODSH sequences, a small number preferentially recognizes a specific binding site on p300. Fluorescence binding studies showed that ODSH bound p300 tightly (dissociation constant ∼1 nM) in a highly cooperative manner. These results suggest that ODSH inhibited HMGB1 release, at least in part, by direct molecular inhibition of p300 HAT activity.

Entities:  

Keywords:  heparin; high mobility group box 1; p300

Mesh:

Substances:

Year:  2017        PMID: 27585400      PMCID: PMC5248960          DOI: 10.1165/rcmb.2016-0069OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  51 in total

1.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

2.  Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis.

Authors:  Maria Entezari; Daniel J Weiss; Ravikumar Sitapara; Laurie Whittaker; Matthew J Wargo; JianHua Li; Haichao Wang; Huan Yang; Lokesh Sharma; Binh D Phan; Mohammad Javdan; Sangeeta S Chavan; Edmund J Miller; Kevin J Tracey; Lin L Mantell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

3.  Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.

Authors:  Mark D Stewart; Vishnu C Ramani; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2014-11-17       Impact factor: 5.157

4.  The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway.

Authors:  Xiaojin Wu; Yanyan Mi; Hui Yang; Ankang Hu; Qingguo Zhang; Chunli Shang
Journal:  Mol Cell Biochem       Date:  2013-05-26       Impact factor: 3.396

5.  Sputum high mobility group box-1 in asthmatic children: a noninvasive sensitive biomarker reflecting disease status.

Authors:  Caterina Cuppari; Sara Manti; Valeria Chirico; Rosangela Caruso; Vincenzo Salpietro; Valentina Giacchi; Francesca Laganà; Teresa Arrigo; Carmelo Salpietro; Salvatore Leonardi
Journal:  Ann Allergy Asthma Immunol       Date:  2015-08       Impact factor: 6.347

6.  HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4.

Authors:  Jean-Marc Tadie; Hong-Beom Bae; Shaoning Jiang; Dae Won Park; Celeste P Bell; Huan Yang; Jean-Francois Pittet; Kevin Tracey; Victor J Thannickal; Edward Abraham; Jaroslaw W Zmijewski
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

7.  Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins.

Authors:  Lianchun Wang; Jillian R Brown; Ajit Varki; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function.

Authors:  Aaron R Winkler; Karl H Nocka; Timothy H Sulahian; Lester Kobzik; Cara M M Williams
Journal:  Exp Lung Res       Date:  2008-11       Impact factor: 2.459

9.  Anti-HMGB1 neutralizing antibody ameliorates neutrophilic airway inflammation by suppressing dendritic cell-mediated Th17 polarization.

Authors:  Fang Zhang; Gang Huang; Bo Hu; Li-Ping Fang; E-Hong Cao; Xiao-Feng Xin; Yong Song; Yi Shi
Journal:  Mediators Inflamm       Date:  2014-05-15       Impact factor: 4.711

10.  AGER -429T/C is associated with an increased lung disease severity in cystic fibrosis.

Authors:  Julie Beucher; Pierre-Yves Boëlle; Pierre-François Busson; Céline Muselet-Charlier; Annick Clement; Harriet Corvol
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

View more
  11 in total

Review 1.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

Review 2.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

Review 3.  Neutrophil Elastase and Chronic Lung Disease.

Authors:  Judith A Voynow; Meagan Shinbashi
Journal:  Biomolecules       Date:  2021-07-21

4.  Molecular principles for heparin oligosaccharide-based inhibition of neutrophil elastase in cystic fibrosis.

Authors:  Apparao B Kummarapurugu; Daniel K Afosah; Nehru Viji Sankaranarayanan; Rahaman Navaz Gangji; Shuo Zheng; Thomas Kennedy; Bruce K Rubin; Judith A Voynow; Umesh R Desai
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

5.  Polymeric fluorescent heparin as one-step FRET substrate of human heparanase.

Authors:  Jyothi C Sistla; Shravan Morla; Al-Humaidi B Alabbas; Ravi C Kalathur; Chetna Sharon; Bhaumik B Patel; Umesh R Desai
Journal:  Carbohydr Polym       Date:  2018-10-28       Impact factor: 9.381

6.  Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.

Authors:  Apparao B Kummarapurugu; Shuo Zheng; Abigail Pulsipher; Justin R Savage; Jonathan Ma; Bruce K Rubin; Thomas P Kennedy; Judith A Voynow
Journal:  Am J Respir Cell Mol Biol       Date:  2021-02       Impact factor: 6.914

Review 7.  Advanced Role of Neutrophils in Common Respiratory Diseases.

Authors:  Jinping Liu; Zhiqiang Pang; Guoqiang Wang; Xuewa Guan; Keyong Fang; Ziyan Wang; Fang Wang
Journal:  J Immunol Res       Date:  2017-05-15       Impact factor: 4.818

Review 8.  Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.

Authors:  Cinzia Lanzi; Giuliana Cassinelli
Journal:  Molecules       Date:  2018-11-08       Impact factor: 4.411

Review 9.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

10.  2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage function.

Authors:  Mao Wang; Alex G Gauthier; Thomas P Kennedy; Haichao Wang; Uday Kiran Velagapudi; Tanaji T Talele; Mosi Lin; Jiaqi Wu; LeeAnne Daley; Xiaojing Yang; Vivek Patel; Sung Soo Mun; Charles R Ashby; Lin L Mantell
Journal:  Mol Med       Date:  2021-07-16       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.